Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

Hong, Yong Sang; Cho, Hyeon Jin; Kim, Sun Young; Jung, Kyung Hae; Park, Ji Won; Choi, Hyo Seong; Oh, Jae Hwan; Kim, Byung Chang; Sohn, Dae Kyung; Kim, Dae Yong; Chang, Hee Jin

doi:10.1186/1471-2407-9-246

BMC Cancer

Article metrics
Last updated: Fri, 10 May 2024 8:27:02 Z

Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer

Access & Citations

5603

Article Accesses
23

Web of Science
24

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com